



Office of the Secretary

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

October 31, 2006

Steven C. Sunshine, Esq.
Cadwalader, Wickersham & Taft LLP
1201 F Street, N.W.
Washington, D.C. 20004

Re: *In the Matter of Watson Pharmaceuticals, Inc., and Andrx Corporation*
File No. 061 0139

Dear Mr. Sunshine:

This letter notifies Watson Pharmaceuticals, Inc. ("Watson") that the Federal Trade Commission has approved the appointment of Mr. Francis J. Civile as the Interim Monitor, and has approved the Interim Monitor Agreement by and between Francis J. Civile and Watson dated July 10, 2006, pursuant to Paragraph VI. of the Decision and Order and Paragraph III. of the Order to Maintain Assets issued in the above-referenced matter.

In according its approval, the Commission has relied upon the information submitted and representations made by Watson and has assumed them to be accurate and complete.

By direction of the Commission, Commissioner Rosch recused.

Donald S. Clark
Secretary

cc: Francis J. Civile
16 Fox Hill Road
Califon, New Jersey 07830